scholarly journals Pertactin-Negative and Filamentous Hemagglutinin-Negative Bordetella pertussis, Australia, 2013–2017

2019 ◽  
Vol 25 (6) ◽  
pp. 1196-1199 ◽  
Author(s):  
Zheng Xu ◽  
Sophie Octavia ◽  
Laurence Don Wai Luu ◽  
Michael Payne ◽  
Verlaine Timms ◽  
...  
Keyword(s):  
Bordetella Pertussis ◽  
Filamentous Hemagglutinin

Restricted antibody response to Bordetella pertussis filamentous hemagglutinin induced by whole-cell and acellular pertussis vaccines

2015 ◽  
Vol 48 (2) ◽  
pp. 127-132 ◽  
Author(s):  
Hossein Asgarian-Omran ◽  
Maryam Golara ◽  
Sara Abdolmaleki ◽  
Shadi Sadat Navabi ◽  
Hadi Alipour ◽  
...  
Keyword(s):  
Antibody Response ◽  
Bordetella Pertussis ◽  
Whole Cell ◽  
Filamentous Hemagglutinin

Recognition of a bacterial adhesin by an integrin: Macrophage CR3 (αMβ2, CD11bCD18) binds filamentous hemagglutinin of Bordetella pertussis

Cell ◽  
1990 ◽  
Vol 61 (7) ◽  
pp. 1375-1382 ◽  
Author(s):  
David Relman ◽  
Elaine Tuomanen ◽  
Stanley Falkow ◽  
Douglas T. Golenbock ◽  
Kirsi Saukkonen ◽  
...  
Keyword(s):  
Bordetella Pertussis ◽  
Filamentous Hemagglutinin ◽  
Bacterial Adhesin

Immunogenicity of a New Enhanced Tetanus-reduced Dose Diphtheria-acellular Pertussis (Tdap) Vaccine Against Bordetella Pertussis in a Murine Model

2020 ◽  
Author(s):  
Kyu Ri Kang ◽  
Dong Ho Huh ◽  
Ji Ahn Kim ◽  
Jin Han Kang
Keyword(s):  
Bordetella Pertussis ◽  
Murine Model ◽  
Booster Vaccination ◽  
Humoral Response ◽  
Mean Value ◽  
Commercial Vaccine ◽  
Reduced Dose ◽  
Filamentous Hemagglutinin ◽  
Tdap Vaccine ◽  
The Mean

Abstract BackgroundThe necessity of the tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccine in adolescence and adults has been emphasized since the resurgence of small-scale pertussis in Korea and worldwide due to the waning effect of the vaccine and variant pathogenic stains in the late 1990s. GreenCross Pharma (GC Pharma), a Korean company, developed the Tdap vaccine GC3111 in 2010. Recently, they enhanced the former vaccine GC3111 to reinforce the antibody response against filamentous hemagglutinin (FHA). In this study, the immunogenicity and efficacy of the enhanced Tdap vaccine were compared and evaluated between the former Tdap vaccine GC3111 and the commercially available Tdap vaccine in a murine model.MethodsBalb/C mice were primed with two doses of the diphtheria-tetanus-acellular pertussis (DTaP) vaccine followed by a single booster Tdap vaccine at 6 weeks using the commercially available Tdap vaccine or 2 Tdap vaccines from GC Pharma (GC3111, enhanced GC3111). Humoral response was assessed 1 week before and 2 and 4 weeks after Tdap booster vaccination. The INF-γ (Th1), IL-5 (Th2), and IL-17 (Th17) cytokines were assessed 4 weeks after booster vaccination by stimulation with three simulators: heat inactivated Bordetella pertussis (hBp), vaccine antigens, and hBp mixed with antigens. An intranasal challenge test was performed 4 weeks after booster vaccination.ResultsThe enhanced GC3111 generated a humoral response to filamentous hemagglutinin (FHA) that was comparable to that of the commercial vaccine. Regarding cell-mediated immunity, cytokine secretion differed among the three simulators. However, no difference was found between the groups. All the vaccinated groups indicated a Th1/Th2 response. The mean value of INF-γ in the control and study groups (simulated with hBp mixed with antigens) was 12,551.69, and the mean value of IL-5 (simulated with antigens) was 1,782.47 pg/mL. On Day 5 post-intranasal challenge, B. pertussis colonies were absent in the lungs in all groups.ConclusionsOur results confirmed the immunogenicity of GC Pharma’s Tdap vaccine; enhanced GC3111 was equivalent to the presently used commercial vaccine in terms of humoral response as well as cell-mediated cytokine expression.

scholarly journals Distinct roles of the N-terminal and C-terminal precursor domains in the biogenesis of the Bordetella pertussis filamentous hemagglutinin.

1996 ◽  
Vol 178 (4) ◽  
pp. 1053-1060 ◽  
Author(s):  
G Renauld-Mongénie ◽  
J Cornette ◽  
N Mielcarek ◽  
F D Menozzi ◽  
C Locht
Keyword(s):  
Bordetella Pertussis ◽  
Filamentous Hemagglutinin

scholarly journals Bordetella pertussis Filamentous Hemagglutinin Enhances the Immunogenicity of Liposome-Delivered Antigen Administered Intranasally

1998 ◽  
Vol 66 (4) ◽  
pp. 1764-1767 ◽  
Author(s):  
Odile Poulain-Godefroy ◽  
Nathalie Mielcarek ◽  
Nathalie Ivanoff ◽  
Franck Remoué ◽  
Anne-Marie Schacht ◽  
...  
Keyword(s):  
Immune Response ◽  
Bordetella Pertussis ◽  
Humoral Immune Response ◽  
Dependent Manner ◽  
Humoral Immune ◽  
Filamentous Hemagglutinin ◽  
Antibody Titers ◽  
Suboptimal Dose ◽  
Outbred Mice ◽  
Dose Dependent

ABSTRACT In an attempt to increase the immunogenicity of mucosally delivered antigens, we incorporated the Bordetella pertussisfilamentous hemagglutinin (FHA) adhesin into liposomes containing the glutathione S-transferase of Schistosoma mansoni (Sm28GST) as a model antigen. Outbred mice immunized twice intranasally with liposomes containing a constant suboptimal dose of Sm28GST and increasing doses of FHA produced anti-Sm28GST antibodies in a FHA dose-dependent manner. The addition of 3 μg of FHA to the liposomes induced more than 10-fold-higher anti-Sm28GST antibody titers, compared to those induced by liposomes without FHA. The presence of FHA did not alter the nature of the humoral immune response, and the sera contained anti-Sm28GST immunoglobulin G1 (IgG1), IgG2a, and IgG2b. However, anti-Sm28GST IgA was only detected when at least 3 μg of FHA was added to the preparation. These results show a promising potential for FHA to enhance the immunogenicity of mucosally administered antigens incorporated into liposomes.

Sign in / Sign up

Export Citation Format

Share Document